128677-61-2

Basic information

• Product Name: (R)-4-BENZYL-2-OXAZOLIDINONE LITHIUM SALT
• Synonyms: (R)-4-BENZYL-2-OXAZOLIDINONE LITHIUM SALT
• CAS NO: 128677-61-2
• Molecular Formula: C₁₀H₁₀NO₂*Li
• Molecular Weight: 185.15
• Mol File: 128677-61-2.mol
• Article Data: 12

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (R)-4-BENZYL-2-OXAZOLIDINONE LITHIUM SALT(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-4-BENZYL-2-OXAZOLIDINONE LITHIUM SALT(128677-61-2)
• EPA Substance Registry System: (R)-4-BENZYL-2-OXAZOLIDINONE LITHIUM SALT(128677-61-2)

Safety Data

• Hazardous Substances Data: 128677-61-2(Hazardous Substances Data)

Upstream product

• 90719-32-7 (S)-4-Benzyl-2-oxazolidinone 

Downstream Products

• 139462-22-9 <4S>-3-<2--N-Methylamino>-1-oxoethyl>-4-(phenylmethyl)-2-oxazolidinone 
• 111292-87-6 (S)-4-benzyl-3-butyryloxazolidin-2-one 
• 202344-78-3 (S)-4-phenylmethyl-3-(1'-oxononanoyl)-2-oxazolidinone 
• 334756-88-6 (S)-4-benzyl-3-undecanoyloxazolidine-2-one 
• 181059-54-1 (S)-3-(2-Benzo[1,3]dioxol-5-yl-acetyl)-4-benzyl-oxazolidin-2-one 
• 191328-35-5 (S)-4-Benzyl-3-[(S)-3-(tert-butyl-diphenyl-silanyloxymethyl)-pent-4-enoyl]-oxazolidin-2-one 
• 191328-26-4 (S)-4-Benzyl-3-[(R)-3-(tert-butyl-diphenyl-silanyloxymethyl)-pent-4-enoyl]-oxazolidin-2-one 
• 170450-77-8 (S)-4-benzyl-3-(3-phenylbutanoyl)oxazolidin-2-one 
• 197590-01-5 (4S,5'E,9'E)-3-(1'-Oxo-6',10',14'-trimethylpentadeca-5',9',13'-trienyl)-4-benzyloxazolidin-2-one 
• 185201-02-9 (S)-4-Benzyl-3-((S)-4-methyl-hexanoyl)-oxazolidin-2-one 
• 222556-16-3 (4S)-4-benzyl-3-[3-{3-(benzyloxy)phenyl}propanoyl]oxazolidin-2-one 
• 313467-78-6 (4S)-4-benzyl-3-(3-[1,1'-biphenyl-4-yl]propanoyl)-1,3-oxazolidin-2-one 
• 204711-93-3 4S-benzyl-3-(6-heptenoyl)-oxazolidin-2-one 

Relevant articles and documents

3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2- CARBOXAMIDE COMPOUNDS

The present invention relates compounds of the formula: or pharmaceutically acceptable salts thereof, useful as sodium channel blockers, as well as compositions containing the same, processes for the preparation of the same, and therapeutic methods of use therefore in promoting hydration of mucosal surfaces and the treatment of diseases including cystic fibrosis, chronic obstructive pulmonary disease, asthma, bronchiectasis, acute and chronic bronchitis, emphysema, and pneumonia.

Asymmetric synthesis of (E)-dehydroapratoxin A

An asymmetric approach to key intermediate 17 starting from lactone 7 is described, in which Evan's alkylation and CBS-catalyzed reduction are used for construction of the chiral centers, respectively. Thus, the synthesis of (E)-dehydroapratoxin A 6 could

N-FORMYL HYDROXYLAMINE COMPOUNDS

Novel N-formyl hydroxylamine compounds and their derivatives are disclosed. These N-formyl hydroxylamine compounds inhibit peptidyl deformylase (PDF), an enzyme present in prokaryotes. The compounds are useful as antimicrobials and antibiotics. The compou